

**ABOUT THE TEST** FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

**PATIENT**

DISEASE Breast carcinoma (NOS)  
 NAME  
 DATE OF BIRTH  
 SEX  
 MEDICAL RECORD #

**PHYSICIAN**

ORDERING PHYSICIAN  
 MEDICAL FACILITY  
 ADDITIONAL RECIPIENT  
 MEDICAL FACILITY ID  
 PATHOLOGIST

**SPECIMEN**

SPECIMEN SITE  
 SPECIMEN ID  
 SPECIMEN TYPE  
 DATE OF COLLECTION  
 SPECIMEN RECEIVED

**Genomic Signatures**

**Microsatellite status - MS-Stable**  
**Tumor Mutational Burden - 5 Muts/Mb**

**Gene Alterations**

*For a complete list of the genes assayed, please refer to the Appendix.*

**AKT3 amplification - equivocal<sup>†</sup>**  
**ERBB2 amplification**  
**RPTOR amplification - equivocal<sup>†</sup>**  
**TP53 Y220C**

**2 Disease relevant genes with no reportable alterations: BRCA1, BRCA2**

<sup>†</sup> See About the Test in appendix for details.

9 Therapies approved in the EU  
 0 Therapies with Lack of Response

20 Clinical Trials

**GENOMIC SIGNATURES**

**Microsatellite status - MS-Stable**

**Tumor Mutational Burden - 5 Muts/Mb**

**GENE ALTERATIONS**

**ERBB2 - amplification**

10 Trials *see p. 15*

**AKT3 - amplification - equivocal**

10 Trials *see p. 13*

**ACTIONABILITY**

No therapies or clinical trials. see Genomic Signatures section

No therapies or clinical trials. see Genomic Signatures section

THERAPIES APPROVED IN THE EU (IN PATIENT'S TUMOR TYPE)		THERAPIES APPROVED IN THE EU (IN OTHER TUMOR TYPE)
Pertuzumab	<input type="checkbox"/> 1	Afatinib
Trastuzumab	<input type="checkbox"/> 1	Dacomitinib
Trastuzumab emtansine	<input type="checkbox"/> 1	
Lapatinib	<input type="checkbox"/> 2A	
Neratinib	<input type="checkbox"/> 2A	
Everolimus		Temsirolimus

NCCN category

GENE ALTERATIONS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS

*For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Alterations section.*

**RPTOR - amplification - equivocal** ..... p. 5    **TP53 - Y220C** ..... p. 5

**NOTE** Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved through a centralized EU procedure or a national procedure in an EU Member State. Therapies, including but not limited to the following, have been approved nationally and may not be available in all EU Member States: Tretinoin, Anastrozole, Bicalutamide, Cyproterone, Exemestane, Flutamide, Goserelin, Letrozole, Leuprolerin, Triptorelin.

PRF#

GENOMIC SIGNATURES

GENOMIC SIGNATURE

## Microsatellite status

RESULT  
MS-Stable

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors<sup>1-3</sup>, including approved therapies nivolumab and pembrolizumab<sup>4</sup>. In a retrospective analysis of 361 patients with solid tumors treated

with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)<sup>5</sup>.

FREQUENCY & PROGNOSIS

No MSI was observed in two large scale analyses of breast cancer samples<sup>6-7</sup>. However, in Lynch syndrome-related breast cancer, MSI has been reported in 51-85% of cases<sup>8-13</sup>. A prospective study observed increased MSI following chemotherapy treatment, and MSI is associated with incidence of secondary tumors<sup>14</sup>.

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of

genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor<sup>15</sup>. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2<sup>15-17</sup>. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers<sup>18-20</sup>. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins<sup>15,17,19-20</sup>.

GENOMIC SIGNATURE

## Tumor Mutational Burden

RESULT  
5 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1<sup>21-23</sup> and anti-PD-1 therapies<sup>21-24</sup>. Higher TMB has corresponded with increased ORR and OS from treatment with immune checkpoint inhibitors in pan-tumor studies<sup>21-24</sup>. Analyses across several solid tumor types have identified that patients with higher TMBs (≥16-20 Muts/Mb) achieved greater clinical benefit using PD-1/PD-L1 monotherapy, compared with patients treated with chemotherapy<sup>25</sup> or those with lower TMBs<sup>22</sup>. Additionally, higher TMB is significantly associated with improved OS with immune checkpoint inhibitor treatment for patients with advanced cancer across 9 solid tumor types<sup>21</sup>.

However, the KEYNOTE 158 trial found significant improvement in ORR in a large cohort of patients with a TMB of ≥10 Muts/Mb compared with those with TMBs <10 across multiple solid tumor types, with similar findings observed in the KEYNOTE 028 and 012 trials<sup>24</sup>. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1/PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Breast carcinoma harbors a median TMB of 3.8 muts/Mb, and 3.1% of cases have high TMB (>20 muts/Mb)<sup>26</sup>. The Breast Invasive Carcinoma TCGA analysis reported an average (non-silent) mutation load of 0.84 muts/Mb for luminal A tumors, 1.38 muts/Mb for luminal B tumors, 2.05 muts/Mb for HER2-enriched tumors, and 1.68 muts/Mb for basal-like tumors<sup>27</sup>. In breast cancer, TMB is significantly higher in recurrent versus primary tumors and CDH1-mutated versus CDH1-wildtype tumors<sup>28</sup>. Higher frequencies of TMB high (>20Mut/mb) have also been reported in metastatic invasive lobular carcinomas (8.9%) compared to metastatic invasive ductal carcinomas (1.6%)<sup>28</sup>. In estrogen receptor-positive breast cancer, increased mutation load (> mean of 1.25 muts/Mb) associated with shorter OS (HR of 2.02)

in an analysis of the TCGA data<sup>29</sup>. In another study, the number of mutated genes associated with higher tumor grade<sup>30</sup>. Although the number of mutated genes did not correlate with OS by multivariate analysis, cases with 22 or more mutated genes had significantly worse OS than cases with fewer than 22 mutated genes (HR of 4.6)<sup>30</sup>.

FINDING SUMMARY

Tumor mutational burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma<sup>31-32</sup> and cigarette smoke in lung cancer<sup>33-34</sup>, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes<sup>35-39</sup>, and microsatellite instability (MSI)<sup>35,38-39</sup>. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types<sup>22-23</sup>.

PRF#

**GENE ALTERATIONS**
**GENE**

# AKT3

**ALTERATION**

amplification - equivocal

**POTENTIAL TREATMENT STRATEGIES**

Activating alterations in AKT3 may predict sensitivity to inhibitors of AKT kinases or the downstream mTOR pathway<sup>40</sup>. Clinical benefit has been achieved in patients with AKT3 amplification treated with an mTOR inhibitor<sup>41</sup>.

**FREQUENCY & PROGNOSIS**

AKT3 amplification has been reported in 5-15% of breast invasive carcinomas<sup>42-44</sup>. AKT3 alterations, including both amplification and deletion, have been reported at higher incidences in triple-negative breast cancer (TNBC, 24%, 20/82) than in ER-positive breast cancers (1%)<sup>45</sup>. AKT3 mRNA is reported to be overexpressed in ER-negative compared to ER-positive breast tumor cell lines, and AKT3 protein and kinase activity were reported to be increased in ER-negative breast cancer cell lines<sup>46</sup>. Increased levels of phosphorylated AKT have been correlated with poor prognosis in patients with breast cancer,

especially in the presence of HER2 expression<sup>47</sup>. Additionally, in patients with TNBC, AKT3 amplification and protein expression were negatively associated with recurrence-free survival<sup>45</sup>.

**FINDING SUMMARY**

AKT3 encodes PKB-gamma, an intracellular serine/threonine kinase. AKT3 is one of three members of the AKT gene family, and activation of AKT3 has been implicated in melanoma and breast cancer<sup>48</sup>. AKT3 has been reported to be amplified in cancer<sup>49</sup> and may be biologically relevant in this context<sup>50-51</sup>.

**GENE**

# ERBB2

**ALTERATION**

amplification

**POTENTIAL TREATMENT STRATEGIES**

On the basis of extensive clinical evidence, ERBB2 amplification or activating mutation may predict sensitivity to therapies targeting HER2, including antibodies such as trastuzumab<sup>52-57</sup>, pertuzumab in combination with trastuzumab<sup>54,58-60</sup>, margetuximab<sup>61</sup>, and ZW25<sup>62</sup> as well as antibody-directed conjugates such as ado-trastuzumab emtansine<sup>63</sup> and fam-trastuzumab deruxtecan<sup>64</sup>, HER2 kinase inhibitors such as tucatinib<sup>65-67</sup>, and dual EGFR/HER2 kinase inhibitors such as lapatinib<sup>68-72</sup>, afatinib<sup>57,73-78</sup>, neratinib<sup>79-80</sup>, dacomitinib<sup>81</sup>, and pyrotinib<sup>82</sup>. For patients with HER2-positive metastatic breast cancer, combining margetuximab<sup>83</sup> or pyrotinib<sup>84-85</sup> with chemotherapy significantly improved PFS or ORRs. The Phase 3 SOPHIA study reported improved median PFS (5.8 vs. 4.9 months, HR=0.76) and ORR (22% vs.16%) when combining margetuximab with chemotherapy, as compared

with trastuzumab and chemotherapy, for patients who had progressed on  $\geq 2$  prior HER2-directed therapies<sup>83</sup>. For patients who had progressed on trastuzumab, the Phase 3 PHENIX study demonstrated improved median PFS (11.1 vs. 4.1 months, HR=0.18) and ORR (69% vs. 16%) for treatment with pyrotinib and capecitabine, as compared with placebo and capecitabine; patients who progressed on the placebo arm and went on to receive single-agent pyrotinib (n=71) achieved median PFS of 5.5 months and ORR of 38%<sup>82</sup>. The same combination elicited an ORR of 91% (10/11) for trastuzumab-naïve patients, and multiple genetic alterations were significantly associated with poorer PFS compared with none or one genetic alteration (16.8 vs. 29.9 months)<sup>84</sup>. In a randomized Phase 2 trial for previously treated patients, the combination of pyrotinib with capecitabine significantly improved ORR (71% vs. 49%, p=0.01) and median PFS (12.6 vs. 5.6 months, HR=0.37) compared with lapatinib and capecitabine irrespective of prior chemotherapy and trastuzumab treatments<sup>85</sup>. In a Phase 1 trial of margetuximab for HER2-overexpressing solid tumors, 12% (7/60) of patients, including 4 with breast, 2 with gastroesophageal, and 1 with lacrimal gland cancers, experienced PRs, and a further 52% (31/60) of the cohort experienced

SD<sup>61</sup>. Early clinical studies aimed at preventing or overcoming resistance to anti-HER2 therapies are underway, including agents targeting the PI3K-AKT pathway or HSP90<sup>86-87</sup>.

**FREQUENCY & PROGNOSIS**

In the TCGA dataset, ERBB2 amplification was detected in 13% of breast invasive carcinoma cases<sup>27</sup>. ERBB2 mutations have been reported in 1-3% of breast invasive carcinoma cases<sup>27,88-89</sup>. The incidence of ERBB2 alterations has been found to be significantly enriched in CDH1-mutated invasive lobular breast cancers<sup>90</sup>. HER2 is predicted to be overexpressed (as assessed by FISH, CNV analysis, or immunohistochemistry) in 12-25% of breast cancers<sup>86,91-92</sup>. Phosphorylated HER2 was expressed in 62.5% (55/88) of HER2-positive breast cancers<sup>93</sup>. Phosphorylated HER2 was associated with development of trastuzumab resistance<sup>93</sup>.

**FINDING SUMMARY**

ERBB2 (also known as HER2) encodes a receptor tyrosine kinase which is in the same family as EGFR. Amplification or overexpression of ERBB2 can lead to excessive proliferation and tumor formation<sup>94</sup>.

PRF#

**GENE ALTERATIONS**
**GENE**  
**RPTOR**
**ALTERATION**  
 amplification - equivocal

**POTENTIAL TREATMENT STRATEGIES**

Several therapeutic approaches that target mTORC1 are under clinical and preclinical investigation, including the FDA-approved mTOR inhibitors everolimus and temsirolimus. Dual mTORC1/mTORC2 inhibitors and dual PI3K/mTOR inhibitors are also under investigation in clinical trials<sup>95-96</sup>. However, objective responses

were not observed in any of 3 patients with breast carcinomas harboring RPTOR amplification treated with everolimus<sup>97-98</sup> and it is unclear whether mTOR inhibitors may be relevant for tumors with RPTOR alterations.

**FREQUENCY & PROGNOSIS**

In the Breast Invasive Carcinoma TCGA dataset, putative high-level amplification of RPTOR has been found in 6% of cases<sup>27</sup>, whereas RPTOR mutations have been reported in approximately 1% of breast carcinomas analyzed<sup>27,43,88,99-100</sup>. RPTOR and mTOR mRNA expression were reported to be higher in breast carcinoma tissues, whereas expression of the mTORC2 component RICTOR was lower in tumor samples<sup>101</sup>. mTORC1

activity has been shown to be upregulated in models of breast cancer<sup>102-103</sup>. Increased mRNA expression of RPTOR and mTOR in breast cancer was associated with higher tumor grade<sup>101</sup>.

**FINDING SUMMARY**

RPTOR encodes regulatory-associated protein of mTOR, which functions as part of the mTORC1 complex. mTORC1 is activated by growth factors and amino acids and plays a role in activation of cellular protein synthesis and maintenance of cell size<sup>104-105</sup>. RPTOR has been reported to be amplified in cancer<sup>49</sup>, and may be biologically relevant in this context<sup>50-51</sup>.

**GENE**  
**TP53**
**ALTERATION**  
 Y220C  
**TRANSCRIPT NUMBER**  
 NM\_000546  
**CODING SEQUENCE EFFECT**  
 659A>G

**POTENTIAL TREATMENT STRATEGIES**

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib<sup>106-109</sup>, or p53 gene therapy and immunotherapeutics such as SGT-53<sup>110-114</sup> and ALT-801<sup>115</sup>. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutant p53 such as APR-246<sup>116-118</sup>. In a Phase 1b trial in patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR<sup>119</sup>. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 10% (17/176) and SDs in 53% (94/176) of patients with solid tumors; the response rate was 21% (4/19) in patients with TP53 mutations versus 12% (4/33) in patients who were TP53 wild-type<sup>120</sup>. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a

32% (30/94, 3 CR) ORR and a 73% (69/94) DCR in patients with platinum refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer<sup>121</sup>. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR in patients with platinum-refractory TP53-mutated ovarian cancer<sup>122</sup>. The combination of adavosertib with paclitaxel and carboplatin in patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone<sup>123</sup>. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate in patients with TP53 alterations<sup>124</sup>. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel in patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage<sup>114</sup>. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutant, but not TP53-wild-type, breast cancer xenotransplant mouse model<sup>125</sup>.

**FREQUENCY & PROGNOSIS**

TP53 is one of the most commonly mutated genes in breast cancer; mutations in this gene have been identified in 27-37% of breast carcinoma samples<sup>27,88,100,126-128</sup>. TP53 mutations that are located within the region encoding the DNA binding domain are associated with poor prognosis in patients with breast cancer<sup>126,129-130</sup>.

TP53 mutation is also implicated in breast cancer susceptibility, as TP53 mutation carriers have an 18-60 fold increased risk for early onset breast cancer<sup>131-133</sup>.

**FINDING SUMMARY**

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers<sup>134</sup>. Any alteration that results in the disruption or partial or complete loss of the region encoding the TP53 DNA-binding domain (DBD, aa 100-292) or the tetramerization domain (aa 325-356), such as observed here, is thought to dysregulate the transactivation of p53-dependent genes and is predicted to promote tumorigenesis<sup>135-137</sup>. The TP53 variant observed here has been described in the ClinVar database as a pathogenic germline mutation (by an expert panel or multiple submitters with no conflicts) associated with Li-Fraumeni syndrome (ClinVar, Nov 2019)<sup>138</sup>. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers<sup>139-141</sup>, including sarcomas<sup>142-143</sup>. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000<sup>144</sup> to 1:20,000<sup>143</sup>. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30<sup>145</sup>. In the appropriate clinical context, germline testing of TP53 is recommended.

PRF#

**THERAPIES APPROVED IN THE EU**
**IN PATIENT'S TUMOR TYPE**

## Everolimus

*Assay findings association*

### AKT3

amplification - equivocal

#### AREAS OF THERAPEUTIC USE

Everolimus is an orally available mTOR inhibitor. It is available in the EU to treat advanced renal cell carcinoma (RCC) following antiangiogenic therapy; unresectable or metastatic, well- or moderately-differentiated, progressive pancreatic neuroendocrine tumors; unresectable or metastatic, well-differentiated non-functional, progressive neuroendocrine tumors of the lung or gastrointestinal tract; and, in association with tuberous sclerosis complex (TSC), renal angiomyolipoma and subependymal giant cell astrocytoma. Everolimus is also available in combination with exemestane to treat postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer following prior therapy with a nonsteroidal aromatase inhibitor.

#### GENE ASSOCIATION

Alterations that activate AKT3 may predict sensitivity to inhibitors of the AKT-mTOR pathway. A PR and significant symptomatic benefit was observed in a male patient with AKT3-amplified breast cancer who was treated with an mTOR inhibitor<sup>40</sup>.

#### SUPPORTING DATA

In a small study, 1 patient with AKT3-amplified, HR-positive metastatic breast cancer achieved clinical benefit > 6 months following combination treatment with anastrozole and everolimus<sup>146</sup>. In an exploratory cohort of the BOLERO-2 Phase 3 study, the addition of exemestane to everolimus in the first line for hormone receptor-positive (HR+), HER2-negative breast cancer was shown to improve the median PFS compared to exemestane alone (11.5 vs. 4.1 months, HR = 0.39)<sup>147</sup>. Everolimus combined with exemestane as second-line therapy in the same setting also improved the median PFS compared with exemestane in BOLERO-2 (7.8 vs. 3.2 months, HR = 0.45)<sup>148-150</sup>, and modestly improved the median PFS compared with everolimus alone in BOLERO-6 (8.4 vs. 6.8 months, HR = 0.74)<sup>151</sup>. Analysis of cell-free DNA

revealed a similar benefit for patients with mutant or wild-type PIK3CA (HR = 0.37 vs. 0.43)<sup>152</sup>. Clinical studies for patients with HR+ breast cancer indicate that everolimus may potentiate letrozole or tamoxifen efficacy and can be safely combined with anastrozole<sup>153-155</sup>. Two Phase 3 trials have evaluated whether the addition of everolimus would circumvent or overcome resistance of HER2-positive (HER2+) breast cancer to trastuzumab-based therapy. As first-line treatment for patients with HER2+ breast cancer, everolimus combined with trastuzumab plus paclitaxel did not significantly improve median PFS in the full study population (15.0 months with everolimus vs. 14.5 months with placebo), but increased PFS in the HR-negative subpopulation (20.3 vs. 13.1 months)<sup>156</sup>. For patients with trastuzumab-resistant HER2+ breast cancer, the addition of everolimus to trastuzumab plus vinorelbine prolonged median PFS (7.0 vs. 5.8 months)<sup>157</sup>. Follow-up exploratory analysis in patients with PIK3CA alterations showed longer median PFS from addition of everolimus to trastuzumab plus either paclitaxel (12.0 vs. 7.6 months) or vinorelbine (6.9 vs. 5.7 months), compared with the addition of placebo to trastuzumab plus either paclitaxel or vinorelbine (HR = 0.69)<sup>158</sup>. Low PTEN expression or PTEN loss also was significantly associated with benefit from added everolimus in the combined analysis of both studies (HR = 0.50), whereas PIK3CA mutation was significantly associated with benefit in HR-negative (HR = 0.43) but not HR+ disease (HR = 0.93)<sup>158-159</sup>. For patients with metastatic triple-negative breast cancer, everolimus plus carboplatin achieved a clinical benefit rate of 36% (9/25)<sup>160</sup>. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors<sup>161</sup>, a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months<sup>162</sup>.

PRF#

THERAPIES APPROVED IN THE EU

IN PATIENT'S TUMOR TYPE

## Lapatinib

*Assay findings association*
**ERBB2**  
 amplification

### AREAS OF THERAPEUTIC USE

Lapatinib inhibits the tyrosine kinases EGFR and ERBB2 (HER2). It is available in the EU to treat patients with HER2-positive advanced breast cancer in combination with capecitabine following prior therapy and in combination with trastuzumab for HER2-positive, hormone receptor (HR)-negative metastatic breast cancer following progression on trastuzumab combined with chemotherapy. It is also available in combination with an aromatase inhibitor to treat postmenopausal women with HER2- and HR-positive metastatic breast cancer.

### GENE ASSOCIATION

Activation or amplification of ERBB2 may predict sensitivity to lapatinib. In one study, a patient with inflammatory breast cancer and ERBB2 V777L and S310F activating mutations, but without ERBB2 amplification or protein overexpression, experienced tumor shrinkage in response to combined treatment with lapatinib and trastuzumab<sup>71</sup>.

### SUPPORTING DATA

Lapatinib as a treatment for HER2+ breast cancer has primarily been investigated in combination with other chemotherapeutic agents, and these combination regimens have been shown to extend PFS and reduce metastases, as well as to extend OS in some instances<sup>68-69,163-166</sup>. As first-line therapy for HER2+ metastatic breast cancer, lapatinib plus taxane resulted in shorter median PFS compared with trastuzumab plus taxane (9.0 vs. 11.3 months, HR of 1.37)<sup>167</sup>. For patients who have progressed on trastuzumab plus taxane, adotrastuzumab emtansine (T-DM1) was superior to lapatinib plus capecitabine (OS of 30.9 vs. 25.1 months)<sup>63</sup>. Addition of lapatinib to capecitabine had improved PFS compared with capecitabine monotherapy (8.4 vs. 4.4 months) in this setting<sup>69</sup>. Lapatinib plus capecitabine has been reported to reduce the number of newly developed brain metastases<sup>63</sup> and to be active against existing brain

metastases (central nervous system [CNS] ORR of 66% [29/44])<sup>168</sup>. However, the incidence of CNS metastases was not significantly different with lapatinib plus capecitabine versus trastuzumab plus capecitabine (3% vs. 5%)<sup>169</sup>, and CNS disease progression rates were similar for treatment with T-DM1 and with lapatinib plus capecitabine<sup>170</sup>. Phase 2 and 3 trials comparing the efficacy of lapatinib and trastuzumab for the treatment of HER2+ breast cancer in the neoadjuvant setting reported conflicting results, with the combination of lapatinib and trastuzumab generally achieving slightly higher response rates<sup>164-166</sup>. A Phase 3 trial of patients with HER2+ breast cancer treated with lapatinib, trastuzumab, or a combination of the two, reported 3-year event-free survival rates of 78%, 76%, and 84%, with 3-year OS rates of 93%, 90%, and 95%, respectively<sup>171</sup>. In a Phase 3 study for patients with early HER2+ breast cancer, adjuvant lapatinib (alone, in sequence, or in combination with trastuzumab) did not significantly improve disease-free survival (DFS) and added toxicity compared with adjuvant trastuzumab<sup>172</sup>. Adjuvant lapatinib also did not significantly extend DFS in a placebo-controlled Phase 3 study<sup>173</sup>. In postmenopausal patients with hormone receptor-positive (HR+) HER2+ metastatic breast cancer, lapatinib combined with letrozole increased median PFS compared to letrozole alone (8.2 vs. 3.0 months)<sup>174</sup>. Addition of lapatinib to fulvestrant did not improve outcome for patients with advanced HR+ advanced breast cancer and prior aromatase inhibitor therapy (median PFS of 4.7 vs. 3.8 months), although lapatinib associated with longer median PFS for HER2+ patients in this trial (5.9 vs. 3.3 months)<sup>175</sup>. As neoadjuvant therapy for HR+ HER2-negative breast cancer, lapatinib combined with letrozole did not significantly improve response rates, but showed a trend toward a higher response rate for patients with PIK3CA-mutant tumors<sup>176</sup>. Four patients with HER3-positive and HER2-negative newly diagnosed breast cancer had clinical responses to neoadjuvant lapatinib<sup>177</sup>.

PRF#

THERAPIES APPROVED IN THE EU

IN PATIENT'S TUMOR TYPE

## Neratinib

*Assay findings association*
**ERBB2**  
 amplification

### AREAS OF THERAPEUTIC USE

Neratinib is an irreversible tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and ERBB4. It is available in the EU for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer who are less than 1 year from the completion of prior adjuvant trastuzumab treatment.

### GENE ASSOCIATION

On the basis of extensive clinical<sup>80,178-181</sup> and preclinical<sup>182-186</sup> evidence, ERBB2 amplification or activating mutations may confer sensitivity to neratinib.

### SUPPORTING DATA

In a Phase 3 study for patients with early stage HER2-positive (HER2+) breast cancer (BC) previously treated with trastuzumab, adjuvant neratinib significantly improved 2-year invasive disease-free survival (iDFS) compared with placebo (93.9% vs. 91.6%, HR=0.67)<sup>180</sup>. The significant iDFS benefit persisted at year 5 of follow-up (90.2% for neratinib vs. 87.7% for placebo, HR=0.73)<sup>187</sup>, including for patients who were also hormone receptor-positive (HR+)<sup>188</sup>; however, the improvement was seen only for those patients who were randomized to neratinib within 12 months of prior trastuzumab treatment<sup>189</sup>. For patients with advanced HER2+ BC previously treated with trastuzumab, a median PFS of 5.6 months from neratinib monotherapy<sup>190</sup>, 4.5 months from neratinib plus capecitabine<sup>191</sup>, and 6.8 months from neratinib plus

lapatinib<sup>191</sup> has been reported in Phase 2 trials; for patients with no prior trastuzumab treatment, neratinib treatment resulted in PFS of 39.6 weeks<sup>190</sup>. For patients with BC and HER2+ brain metastases treated with neratinib, the central nervous system (CNS) ORR was 7.5% (3/40)<sup>192</sup>. The Phase 3 NALA study reported a 24% reduction in risk of disease progression (HR=0.76) with neratinib and capecitabine, as compared with lapatinib and capecitabine, for patients with HER2+ metastatic breast cancer (MBC) and progression on 2 or more prior HER2-directed therapies; neratinib also improved the time to intervention for symptomatic CNS disease compared with lapatinib (overall cumulative incidence 22.8% vs. 29.2%, P=0.043)<sup>193</sup>. Also for patients with HER+ MBC, Phase 1 and Phase 1/2 trials reported an ORR of 73% for neratinib plus paclitaxel<sup>194</sup>, an ORR of 38% and a clinical benefit rate of 52% from neratinib with trastuzumab<sup>195</sup>, and a higher ORR from neratinib and vinorelbine for patients who were lapatinib-naïve (41%) as compared with those patients who had prior lapatinib treatment (8%)<sup>196</sup>. As first-line therapy in HER2+ MBC, PFS or ORR did not significantly differ with neratinib plus paclitaxel compared with trastuzumab plus paclitaxel; however, patients treated with neratinib had a lower incidence of CNS disease recurrence<sup>197</sup>. As neoadjuvant treatment in HER2+, HR-negative BC, the pathologic CR rate was 56% for neratinib plus paclitaxel as compared with 33% for trastuzumab plus paclitaxel<sup>181</sup>.



PRF#

**THERAPIES APPROVED IN THE EU**
**IN PATIENT'S TUMOR TYPE**

## Pertuzumab

*Assay findings association*
**ERBB2**  
 amplification

### AREAS OF THERAPEUTIC USE

Pertuzumab is a monoclonal antibody that interferes with the interaction between HER2 and ERBB3. It is available in the EU in combination with trastuzumab and docetaxel to treat patients with HER2-positive (HER2+) metastatic or unresectable breast cancer who have not received prior chemotherapy or HER2-targeted therapy. It is also available in combination with trastuzumab and chemotherapy as neoadjuvant treatment for HER2+; locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence; and as adjuvant treatment for patients with HER2+ early breast cancer at high risk of recurrence.

### GENE ASSOCIATION

On the basis of clinical studies in multiple tumor types, ERBB2 amplification or activating mutations may predict sensitivity to pertuzumab<sup>58-59,198-201</sup>.

### SUPPORTING DATA

In the APHINITY trial, addition of pertuzumab to chemotherapy plus trastuzumab as adjuvant treatment for patients with HER2+ early stage breast cancer improved the estimated 3-year rate of invasive disease-free survival compared with placebo (94.1% vs. 93.2%), with greater improvement seen for patients with node-positive [92.0% vs. 90.2%, hazard ratio (HR) = 0.77] than those with node-negative (97.5% vs. 98.4%, HR = 1.13) disease<sup>199</sup>. The CLEOPATRA Phase 3 randomized trial for patients with HER2+ metastatic breast cancer (MBC) reported that, compared to placebo, addition of pertuzumab to first-line trastuzumab and docetaxel demonstrated a significant improvement in progression-free survival (PFS; 12.4 vs. 18.7 months) and in median overall survival (OS; 40.8 vs.

56.5 months)<sup>58-59,201</sup>. A Phase 2 study in patients with locally advanced breast cancer (LABC) or HER2+ early stage breast cancer with various combinations of pertuzumab, trastuzumab, and docetaxel reported the greatest benefit when using neoadjuvant pertuzumab combined with trastuzumab and docetaxel (5-year PFS rate of 84)<sup>202-203</sup>. In the KRISTINE Phase 3 trial, patients with HER2+ stage II-III breast cancer treated in the neoadjuvant setting with trastuzumab emtansine plus pertuzumab showed a reduced number of pathological complete responses (44.4%) compared with traditional trastuzumab, pertuzumab, and chemotherapy (55.7%), although more Grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group<sup>198</sup>. A study of pertuzumab combined with paclitaxel and ado-trastuzumab emtansine reported an overall response rate of 52.4% in patients with previously treated HER2+ MBC or LABC<sup>204</sup>. In a Phase 3 study of patients with HER2+ MBC failing on first-line trastuzumab, addition of pertuzumab to trastuzumab and capecitabine was reported to increase median PFS (11.1 vs. 9.0 months) and OS (36.1 vs. 28.1 months) when compared with trastuzumab plus capecitabine<sup>205</sup>. A trial of 12 patients with HER2+ MBC progressing on pertuzumab plus trastuzumab reported 1 complete response (CR), 1 partial response (PR), and 5 stable diseases (SD) after treatment with a combination of pertuzumab, trastuzumab, and gemcitabine<sup>206</sup>. A Phase 1 trial of salvage therapy with a combination of pertuzumab, trastuzumab, and gemcitabine for 6 patients with HER2+ MBC after progression on trastuzumab reported 1 PR, 4 SD, 1 progressive disease, and a median PFS of 3.8 months<sup>207</sup>.

THERAPIES APPROVED IN THE EU IN PATIENT'S TUMOR TYPE

PRF#

## Trastuzumab

Assay findings association

**ERBB2**  
amplification

### AREAS OF THERAPEUTIC USE

Trastuzumab is a monoclonal antibody that targets the protein ERBB2/HER2. It is available in the EU as monotherapy and in combination with other therapies for HER2-positive (HER2+) metastatic and early breast carcinoma and in combination with chemotherapy for HER2+ metastatic gastric or gastroesophageal adenocarcinoma. Trastuzumab biosimilars are also available in the EU for these indications.

### GENE ASSOCIATION

On the basis of clinical studies in multiple tumor types, ERBB2 amplification, overexpression, or activating mutations may confer sensitivity to trastuzumab<sup>52-53,57,71,200,208-211</sup>.

### SUPPORTING DATA

In a study of patients with early breast cancer treated with neoadjuvant trastuzumab, higher ERBB2 copy number (HER2/CEP17 ratio >6) correlated with increased incidence of pathologic CR compared to lower ERBB2 copy number<sup>212</sup>. Trastuzumab has been approved for patients with HER2+ breast cancer based on multiple Phase 2 and 3 clinical trials<sup>52,58,201</sup>. Trastuzumab biosimilars demonstrated comparable clinical benefit to trastuzumab in patients with HER2+ breast cancer<sup>213-222</sup>. A Phase 3 study of patients with HER2+ breast cancer reported 5-year event-free survival (EFS) in 58% of patients treated with trastuzumab plus neoadjuvant therapy, compared to 43% in patients treated with neoadjuvant therapy alone<sup>208</sup>. A long-term follow-up

Phase 2 analysis reported 5-year distant disease-free survival (DFS) rates of 92% in patients with HER2+ breast cancer treated with chemotherapy and trastuzumab and 89% in patients treated with lapatinib and chemotherapy<sup>209</sup>. A Phase 3 trial of patients with HER2+ breast cancer treated with lapatinib, trastuzumab, or a combination of both reported 3-year EFS rates of 78%, 76%, and 84%, and 3-year OS rates of 93%, 90%, and 95%, respectively<sup>171</sup>. Two Phase 3 studies comparing 6-month to 12-month adjuvant trastuzumab reported similar DFS rates for patients with HER2+ early breast cancer after 5.4 years (89.4% vs. 89.8%, HR=1.07)<sup>223</sup> or 7.5 years median follow-up (78.8% vs. 79.6%, HR=1.08)<sup>224</sup>. A Phase 1b study of trastuzumab in combination with the HER2 TKI tucatinib for patients with HER2+ metastatic breast cancer previously treated with HER2-targeting agents reported a 40% (6/15) ORR and median PFS of 5.5 months; an ORR of 61% (14/23, 1 CR) and median PFS of 7.8 months was reported when capecitabine was added to the combination. In the patients with brain metastases, 42% (5/12, 1 CR) exhibited brain-specific responses<sup>66</sup>. As first-line treatment for patients with HER2+ breast cancer, everolimus combined with trastuzumab plus paclitaxel did not significantly improve median PFS in the full study population (15.0 months with everolimus vs. 14.5 months with placebo) but increased PFS in the HR-negative subpopulation by 7.2 months (20.3 vs. 13.1 months)<sup>156</sup>. For patients with trastuzumab-resistant HER2+ breast cancer, the addition of everolimus to trastuzumab plus vinorelbine prolonged median PFS (7.0 vs. 5.8 months)<sup>157</sup>.

## Trastuzumab emtansine

Assay findings association

**ERBB2**  
amplification

### AREAS OF THERAPEUTIC USE

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that targets the protein ERBB2/HER2 on the cell surface, inhibiting HER2 signaling; it also releases the cytotoxic therapy DM1 into cells, leading to cell death. T-DM1 is available in the EU to treat patients with HER2-positive (HER2+) advanced breast carcinoma and disease progression on prior therapy.

### GENE ASSOCIATION

ERBB2 amplification or activating mutations may predict sensitivity to T-DM1.

### SUPPORTING DATA

For patients with HER2+ breast cancer (BC) previously treated with HER2-directed therapies, Phase 3 trials of single-agent T-DM1 have reported significant increases in median PFS as compared with physician's choice of therapy (6.2 vs. 3.3 months)<sup>225</sup> or lapatinib plus capecitabine (9.6 vs. 6.4 months)<sup>63,226-227</sup>. The Phase 3 MARIANNE study for patients with HER2+ advanced BC treated in the first line with T-DM1 reported no significant differences in ORR (60%, 64%, and 68%) or median PFS (14.1, 15.2, and 13.7 months) when comparing T-DM1 combined with placebo, T-DM1 with pertuzumab,

and trastuzumab with a taxane, respectively<sup>228</sup>; however, an earlier Phase 2 study reported improved median PFS with T-DM1 as compared with trastuzumab plus docetaxel (14.2 months vs. 9.2 months, HR=0.59) in this setting<sup>229</sup>. In the Phase 3 KATHERINE study, patients with HER2+ early BC with residual invasive disease following completion of neoadjuvant taxane and trastuzumab treated with T-DM1 experienced significantly higher invasive disease-free survival rates at 3 years (88.3% vs. 77.0%, HR=0.50) compared with patients treated with trastuzumab<sup>230</sup>. In the neoadjuvant setting, the Phase 3 KRISTINE study for patients with HER2+ BC reported a lower pathologic CR rate (44.4% vs. 55.7%, p=0.016) with T-DM1 plus pertuzumab compared with the combination of trastuzumab, pertuzumab, docetaxel, and carboplatin<sup>231</sup>. Patients with HER2+ locally advanced BC or metastatic BC (MBC) have experienced clinical benefit in Phase 1/2 studies from T-DM1 in combination with docetaxel<sup>232</sup>, paclitaxel and pertuzumab<sup>204</sup>, neratinib<sup>233</sup>, alpelisib<sup>234</sup>, and tucatinib<sup>233</sup>. A retrospective analysis found that patients with HER2+ MBC and active central nervous system (CNS) metastases treated with T-DM1 achieved an ORR of 40% (4/10); there was no significant OS difference between patients with and without CNS metastases<sup>235</sup>.

PRF#

THERAPIES APPROVED IN THE EU | IN OTHER TUMOR TYPE

## Afatinib

Assay findings association

**ERBB2**  
amplification

### AREAS OF THERAPEUTIC USE

Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is available in the EU to treat patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR mutations and for the treatment of patients with advanced squamous NSCLC after progression on platinum-based chemotherapy.

### GENE ASSOCIATION

Clinical and preclinical data support sensitivity of multiple activating mutations in ERBB2, including A775\_G776insYVMA and P780\_Y781insGSP, to afatinib<sup>236-243</sup>. Studies have reported DCRs of 54 to 70% for patients with ERBB2-mutated NSCLC treated with afatinib, most of whom harbored exon 20 insertions<sup>236-239</sup>.

### SUPPORTING DATA

In a Phase 3 study for patients with HER2-positive (HER2+) breast cancer and disease progression on trastuzumab, afatinib plus vinorelbine compared to

trastuzumab plus vinorelbine did not improve median PFS (5.5 vs. 5.6 months) or ORR (46% vs. 47%), associated with shorter median OS (20.5 vs. 28.6 months), and was less well tolerated<sup>244</sup>. Afatinib monotherapy achieved an ORR of 11% (4/35) and a median OS of 61 weeks in this setting<sup>74</sup>. For patients with progressive brain metastases after HER2-targeted therapy, treatment with afatinib alone, afatinib combined with vinorelbine, or investigator's choice did not increase patient benefit (12/40 vs. 13/38 vs. 18/43) and caused frequent adverse events<sup>245</sup>. As neoadjuvant treatment for HER2+ breast cancer, afatinib demonstrated a comparable or higher ORR (80%, 8/10) than lapatinib (75%, 6/8) or trastuzumab (36%, 4/11); however, adverse events were more frequent than with lapatinib or trastuzumab<sup>246</sup>. In contrast, a Phase 2 trial reported no objective responses for genomically unselected patients with HER2-negative breast cancer<sup>247</sup>. Afatinib plus letrozole achieved SD for 54% (15/28) of patients with estrogen receptor-positive breast cancer who had progressed on single-agent letrozole<sup>248</sup>.

## Dacomitinib

Assay findings association

**ERBB2**  
amplification

### AREAS OF THERAPEUTIC USE

Dacomitinib is a second-generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is available in the EU for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations.

### GENE ASSOCIATION

On the basis of strong clinical<sup>81,249-252</sup> and preclinical<sup>253-256</sup> data, ERBB2 amplification or activating mutation may indicate sensitivity to dacomitinib.

### SUPPORTING DATA

Clinical data on the efficacy of dacomitinib for the treatment of breast carcinoma are limited (PubMed, Aug 2019). Investigations into the efficacy of dacomitinib have primarily been in the context of non-small cell lung cancer (NSCLC). Patients with EGFR-mutant NSCLC

treated with dacomitinib exhibited significant improvement in OS compared with gefitinib treatment (median OS, 34.1 vs. 26.8 months)<sup>257-258</sup>. A Phase 2 study of dacomitinib in patients with advanced penile squamous cell carcinoma (SCC) reported an ORR of 32% (1 CR, 8 PR), including a 100% DCR (1 CR, 1 PR, 2 SD) in four patients with EGFR amplification<sup>259-260</sup>. A Phase 2 study of dacomitinib in patients with recurrent or metastatic head and neck SCC reported clinical benefit (defined as PFS>4 months) in 13/31 (42%) of patients<sup>251</sup>. Studies of dacomitinib in esophageal<sup>261</sup> and cutaneous<sup>262</sup> SCC reported RRs of 12.5% (6/48) and 28.6% (12/42), respectively, but high DCRs of 73% and 86%, respectively. In contrast, trials of dacomitinib in heavily pretreated patients with HER2+ gastric cancer<sup>252</sup> and patients with EGFR-amplified glioblastoma<sup>263</sup> found RRs of fewer than 10% and DCRs of fewer than 50%: 11/27 (41%) DCR in HER2+ gastric cancer<sup>252</sup> and 15/49 (31%) in EGFR-amplified glioblastoma<sup>263</sup>.

PRF#

THERAPIES APPROVED IN THE EU IN OTHER TUMOR TYPE

# Temsirolimus

Assay findings association

**AKT3**  
amplification - equivocal

### AREAS OF THERAPEUTIC USE

Temsirolimus is an intravenous mTOR inhibitor. It is available in the EU to treat advanced renal cell carcinoma (RCC) and relapsed or refractory mantle cell lymphoma (MCL).

### GENE ASSOCIATION

Alterations that activate AKT3 may predict sensitivity to inhibitors of the AKT-mTOR pathway. A PR and significant symptomatic benefit was observed in a male patient with AKT3-amplified breast cancer who was treated with an mTOR inhibitor<sup>40</sup>.

### SUPPORTING DATA

A Phase 1 trial examining the combination of temsirolimus, liposomal doxorubicin, and bevacizumab in 74 patients with breast and gynecological malignancies reported that 37.9% of patients experienced either a CR (1.4%), PR (18.9%), or SD (17.6%); among 25 patients with

PIK3CA mutation or PTEN loss, 52% experienced a CR, PR (36%), or SD (16%)<sup>264</sup>. Another Phase 1 trial including patients with several types of cancer reported a 42% incidence of complete or partial responses in patients with metastatic breast cancer<sup>265</sup>. However, a Phase 2 study of temsirolimus in pretreated patients with metastatic breast cancer reported minimal clinical activity and no association with PTEN protein or PIK3CA mutation status<sup>266</sup>. A Phase 3 placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer was terminated at the second interim since the addition of temsirolimus to letrozole did not improve PFS as a first-line therapy<sup>267</sup>. A study examining the efficacy of temsirolimus-involving regimens in 24 patients with mesenchymal/metaplastic breast cancer (MpBCs) reported 2 CRs, 4 PRs, 2 instances of SD longer than 6 months, and 4 instances of SD shorter than 6 months<sup>268</sup>.

**NOTE** Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies listed in this report may not be complete and exhaustive and the therapeutic agents are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type.

PRF#

**CLINICAL TRIALS**

**IMPORTANT** Clinical trials are ordered by gene and prioritized in the following descending order: Pediatric trial qualification → Geographical proximity → Trial phase → Trial verification within last 2 months. While every effort is made to ensure the accuracy of the information

contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. The clinical trials listed in this report may not be complete and exhaustive or may include trials for which the patient does not meet the

clinical trial enrollment criteria. For additional information about listed clinical trials or to conduct a search for additional trials, please see [clinicaltrials.gov](http://clinicaltrials.gov) or local registries in your region.

**GENE**  
**AKT3**

**ALTERATION**  
 amplification - equivocal

**RATIONALE**  
 AKT3 amplification or activating mutations may lead to AKT-mTOR pathway activation and may

predict sensitivity to inhibitors of this pathway.

**NCT03182634**
**PHASE 2**

The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic Choices (plasmaMATCH) Trial

**TARGETS**  
 ER, EGFR, ERBB2, ERBB4, AKTs, PARP, ATR

**LOCATIONS:** Sutton (United Kingdom), Bournemouth (United Kingdom), Bristol (United Kingdom), Cambridge (United Kingdom), Cardiff (United Kingdom), Edinburgh (United Kingdom), Exeter (United Kingdom), Glasgow (United Kingdom), Liverpool (United Kingdom), London (United Kingdom), Maidstone (United Kingdom), Manchester (United Kingdom), Oxford (United Kingdom), Plymouth (United Kingdom), Sheffield (United Kingdom), Southampton (United Kingdom), Truro (United Kingdom)

**NCT03673787**
**PHASE 1/2**

A Trial of Ipatasertib in Combination With Atezolizumab

**TARGETS**  
 AKTs, PD-L1

**LOCATIONS:** Sutton (United Kingdom)

**NCT03994796**
**PHASE 2**

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

**TARGETS**  
 ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR

**LOCATIONS:** Alaska, Arkansas, California, Colorado, Georgia, Idaho, Illinois, Iowa, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming

**NCT03366103**
**PHASE 1/2**

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

**TARGETS**  
 mTORC1, mTORC2, BCL-W, BCL-XL, BCL2

**LOCATIONS:** Maryland, Massachusetts, New Jersey, New York

**NCT01827384**
**PHASE 2**

Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors

**TARGETS**  
 PARP, mTOR, MEK, WEE1

**LOCATIONS:** Colorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas

PRF#

**CLINICAL TRIALS**
**NCT03297606**
**PHASE 2**

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

**TARGETS**  
 VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, PDGFRs, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, BRAF, MEK, SMO

**LOCATIONS:** Vancouver (Canada), Kingston (Canada), London (Canada), Ottawa (Canada), Toronto (Canada), Montreal (Canada), Regina (Canada), Saskatoon (Canada)

**NCT03154281**
**PHASE 1**

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast

**TARGETS**  
 PARP, mTOR

**LOCATIONS:** South Dakota

**NCT02719691**
**PHASE 1**

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

**TARGETS**  
 Aurora kinase A, mTORC1, mTORC2

**LOCATIONS:** Colorado

**NCT04032080**
**PHASE 2**

Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib

**TARGETS**  
 CHK1, mTOR, PI3K

**LOCATIONS:** Texas

**NCT02159989**
**PHASE 1**

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

**TARGETS**  
 PIGF, VEGFA, VEGFB, mTORC1, mTORC2

**LOCATIONS:** Texas

**CLINICAL TRIALS**

PRF#

**GENE**  
**ERBB2**

**ALTERATION**  
amplification

**RATIONALE**  
ERBB2 amplification or activating mutation may confer sensitivity to HER2-targeted and dual

EGFR/HER2-directed therapies, and may enhance efficacy of HSP90 inhibitors.

**NCT03523585**

**PHASE 3**

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

**TARGETS**  
ERBB2, EGFR

**LOCATIONS:** Arizona, Badalona (Spain), L'Hospitalet De Llobregat (Spain), Marseille cedex 20 (France), California, Caen Cedex 05 (France), Cheongju-si (Korea, Republic of), Connecticut, Truro (United Kingdom), Plérin (France), Jerez De La Frontera (Spain), Exeter (United Kingdom), Plymouth (United Kingdom), District of Columbia, Besançon (France), Brest Cedex (France), Florida, Fukushima-shi (Japan), Georgia, Aberdeen (United Kingdom), London (United Kingdom), Incheon (Korea, Republic of), Seongnam-si (Korea, Republic of), Suwon-si (Korea, Republic of), Antony (France), Saint-Cloud (France), Montpellier (France), Rennes cedex (France), Illinois, Indiana, Kentucky, A Coruña (Spain), Edinburgh (United Kingdom), Maine, Maryland, Massachusetts, Michigan, Monza (Italy), Missouri, Darlinghurst (Australia), Liverpool (Australia), Sydney (Australia), Tweed Heads (Australia), New York, Lille cedex (France), Valenciennes (France), Nottingham (United Kingdom), Ohio, Osakasayama-shi (Japan), Ōsakasayama-shi (Japan), Paris Cedex 05 (France), Pennsylvania, Aviano (Italy), Bayonne Cedex (France), Woolloongabba (Australia), Pierre Benite cedex (France), Itajaí (Brazil), Le Mans Cedex 02 (France), Rouen (France), San Cristobal de la Laguna (Spain), Tennessee, Texas, Chuo Ku (Japan), Utah, Avignon Cedex 9 (France), Villejuif cedex (France), Box Hill (Australia), Frankston (Australia), Heidelberg (Australia), Melbourne (Australia), Saint Albans (Australia), Virginia, Washington, Subiaco (Australia), Bruxelles (Belgium), Gent (Belgium), Kortrijk (Belgium), Leuven (Belgium), Namur (Belgium), Rio De Janeiro (Brazil), São Paulo (Brazil), Brno (Czechia), Prague 5 (Czechia), Praha (Czechia), Paris (France), Athens (Greece), Heraklion (Greece), Thessaloniki (Greece), Haifa (Israel), Jerusalem (Israel), Kfar Saba (Israel), Petah tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Bergamo (Italy), Bologna (Italy), Genova (Italy), Lecco (Italy), Messina (Italy), Milano (Italy), Modena (Italy), Napoli (Italy), Padova (Italy), Parma (Italy), Pavia (Italy), Pisa (Italy), Torino (Italy), Ehime (Japan), Fukuoka (Japan), Hiroshima (Japan), Hokkaido (Japan), Hyōgo (Japan), Kanagawa (Japan), Kyoto (Japan), Miyagi (Japan), Nagoya (Japan), Niigata (Japan), Okayama (Japan), Osaka (Japan), Saitama (Japan), Shizuoka (Japan), Tokyo (Japan), Daegu (Korea, Republic of), Goyang-si (Korea, Republic of), Seoul (Korea, Republic of), Badajoz (Spain), Barcelona (Spain), Lleida (Spain), Madrid (Spain), Salamanca (Spain), Sevilla (Spain), Valencia (Spain), Adana (Turkey), Ankara (Turkey), Antalya (Turkey), Istanbul (Turkey), Sakarya (Turkey), Samsun (Turkey), Tekirdağ (Turkey), İzmir (Turkey)

**NCT03529110**

**PHASE 3**

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

**TARGETS**  
ERBB2

**LOCATIONS:** Calgary (Canada), Salvador (Brazil), L'Hospitalet De Llobregat (Spain), Strasbourg Cedex (France), Beijing (China), Marseille Cedex 20 (France), California, Caen Cedex 05 (France), Plérin (France), Exeter (United Kingdom), District of Columbia, Besançon (France), Florida, Georgia, Aberdeen (United Kingdom), London (United Kingdom), Manchester (United Kingdom), Goyang-si (Korea, Republic of), Seongnam-si (Korea, Republic of), Harbin (China), Montpellier (France), Rennes cedex (France), Illinois, Kentucky, Saint-Herblain (France), Edinburgh (United Kingdom), Maryland, Massachusetts, Monza (Italy), Rozzano (Italy), Missouri, Nebraska, New York, Valenciennes (France), North Carolina, Nottingham (United Kingdom), Ohio, Toronto (Canada), Pennsylvania, Aviano (Italy), Montréal (Canada), Woolloongabba (Australia), Lyon Cedex 08 (France), Pierre Benite Cedex (France), Itajaí (Brazil), São Paulo (Brazil), LeMans Cedex 02 (France), Sevilla (Spain), San Cristobal de la Laguna (Spain), Tennessee, Texas, Utah, Avignon Cedex 9 (France), Saint-Mandé (France), Villejuif cedex (France), Box Hill (Australia), Frankston (Australia), Melbourne (Australia), Washington, Subiaco (Australia), Hangzhou (China), Bruxelles (Belgium), Edegem (Belgium), Gent (Belgium), Leuven (Belgium), Namur (Belgium), Rio De Janeiro (Brazil), Paris (France), Hong Kong (Hong Kong), Shatin (Hong Kong), Bergamo (Italy), Genova (Italy), Lecco (Italy), Messina (Italy), Milano (Italy), Modena (Italy), Napoli (Italy), Torino (Italy), Aichi (Japan), Fukuoka (Japan), Hiroshima (Japan), Hokkaido (Japan), Kanagawa (Japan), Kumamoto (Japan), Niigata (Japan), Osaka (Japan), Saitama (Japan), Tokyo (Japan), Seoul (Korea, Republic of), Badajoz (Spain), Barcelona (Spain), Madrid (Spain), Málaga (Spain), Taichung (Taiwan), Tainan (Taiwan), Taipei (Taiwan)

**NCT03726879**

**PHASE 3**

A Study To Evaluate The Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

**TARGETS**  
PD-L1, ERBB3, ERBB2

**LOCATIONS:** Calgary (Canada), Salvador (Brazil), Badalona (Spain), Vancouver (Canada), Napoli (Italy), Aviano (Italy), Goiania (Brazil), Obninsk (Russian Federation), Roma (Italy), Monza (Italy), Rozzano (Italy), Missouri, Moskva (Russian Federation), Pamplona (Spain), New York, Candiolo (Italy), Montréal (Canada), Quebec City (Canada), Porto Alegre (Brazil), Sao Paulo (Brazil), Tennessee, Padova (Italy), Olomouc (Czechia), Bad Nauheim (Germany), Essen (Germany), Freiburg (Germany), Hamburg (Germany), Leipzig (Germany), Münster (Germany), Trier (Germany), Ehime (Japan), Fukushima (Japan), Hiroshima (Japan), Hokkaido (Japan), Kanagawa (Japan), Kumamoto (Japan), Niigata (Japan), Osaka (Japan), Tokyo (Japan), Seoul (Korea, Republic of), Gliwice (Poland), Grudziądz (Poland), Kraków (Poland), Warszawa (Poland), Wrocław (Poland), Łódź (Poland), Moscow (Russian Federation), Barcelona (Spain), Burgos (Spain), Granada (Spain), Jaen (Spain), Lerida (Spain), Madrid (Spain), Sevilla (Spain), Taipei (Taiwan), Taipei City (Taiwan), Taoyuan (Taiwan)

PRF#

**CLINICAL TRIALS**
**NCT03262935**
**PHASE 3**

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

**TARGETS**  
 ERBB2, EGFR

**LOCATIONS:** Alabama, Arizona, California, Florida, Nijmegen (Netherlands), Illinois, Kansas, Maryland, Michigan, Missouri, Amsterdam (Netherlands), North Carolina, Ohio, Oregon, Pennsylvania, Texas, Virginia, Brussel (Belgium), Bruxelles (Belgium), Edegem (Belgium), Gent (Belgium), Kortrijk (Belgium), Leuven (Belgium), Liege (Belgium), Edmonton (Canada), Kelowna (Canada), Montreal (Canada), Ottawa (Canada), Naestved (Denmark), Odense (Denmark), Sønderborg (Denmark), Angers (France), Bordeaux (France), Dijon (France), Lille (France), Metz (France), Nantes (France), Paris (France), Pierre-Benite (France), Rouen (France), Strasbourg (France), Bari (Italy), Bologna (Italy), Catania (Italy), Firenze (Italy), Milano (Italy), Modena (Italy), Monza (Italy), Padova (Italy), Prato (Italy), Roma (Italy), San Giovanni Rotondo (Italy), Groningen (Netherlands), Singapore (Singapore), Alicante (Spain), Barcelona (Spain), Lleida (Spain), Madrid (Spain), Valencia (Spain), Zaragoza (Spain), Gävle (Sweden), Göteborg (Sweden), Stockholm (Sweden), Uppsala (Sweden), Bebington (United Kingdom), Cardiff (United Kingdom), Glasgow (United Kingdom), London (United Kingdom), Manchester (United Kingdom), Oxford (United Kingdom)

**NCT03595592**
**PHASE 3**

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

**TARGETS**  
 ERBB3, ERBB2, PD-L1

**LOCATIONS:** Milano (Italy), Negrar (Italy), Pavia (Italy), Reggio Emilia (Italy), Rimini (Italy), Roma (Italy), Udine (Italy), A Coruña (Spain), Badajoz (Spain), Barcelona (Spain), Madrid (Spain), Málaga (Spain), Valencia (Spain)

**NCT02947685**
**PHASE 3**

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

**TARGETS**  
 ERBB2, Aromatase, ER, CDK4, CDK6, ERBB3

**LOCATIONS:** California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Clayton (Australia), Darlinghurst (Australia), Garran (Australia), Melbourne (Australia), Nedlands (Australia), South Brisbane (Australia), Waratah (Australia), Westmead (Australia), Angers (France), Avignon (France), Bordeaux (France), Caen (France), Cholet (France), Clermont-Ferrand (France), Dijon (France), Limoges (France), Lyon (France), Marseille (France), Nice (France), Paris (France), Plerin Cedex (France), Reims (France), Rouen (France), Saint-Cloud (France), Saint-Priest-en-Jarez (France), Strasbourg (France), Toulouse (France), Villejuif (France), Berlin (Germany), Bielefeld (Germany), Bottrop (Germany), Düsseldorf (Germany), Essen (Germany), Frankfurt (Germany), Hameln (Germany), Hannover (Germany), Karlsruhe (Germany), Kiel (Germany), Köln (Germany), Munster (Germany), Münster (Germany), Oldenburg (Germany), Schweinfurt (Germany), Wiesbaden (Germany), Segrate (Italy), Auckland (New Zealand), Barcelona (Spain), Madrid (Spain), Murcia (Spain), Málaga (Spain), Navarro (Spain), Salamanca (Spain), Santiago (Spain), Seville (Spain), Tarragona (Spain), Valencia (Spain)

**NCT02627274**
**PHASE 1**

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

**TARGETS**  
 FAP, ERBB2, EGFR

**LOCATIONS:** Arizona, Meldola (Italy), Milano (Italy), Missouri, Hamilton (Canada), Toronto (Canada), Edegem (Belgium), Bordeaux (France), Toulouse (France), VILLEJUIF Cedex (France), Amsterdam (Netherlands), Rotterdam (Netherlands), Leicester (United Kingdom), London (United Kingdom), Manchester (United Kingdom)

**NCT03523572**
**PHASE 1/2**

Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer

**TARGETS**  
 PD-1, ERBB2

**LOCATIONS:** California, Connecticut, London (United Kingdom), Florida, Kentucky, New York, North Carolina, Ohio, Tennessee, Utah, Washington, Brussels (Belgium), Wilrijk (Belgium), Milano (Italy), Siena (Italy), Madrid (Spain), London Borough of Sutton (United Kingdom)



PRF#

**CLINICAL TRIALS**
**NCT03144947**
**PHASE 2**

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer

**TARGETS**  
 ERBB2, ERBB3

**LOCATIONS:** Negrar (Italy), Bergamo (Italy), Parma (Italy), Piacenza (Italy), Reggio Emilia (Italy), Rimini (Italy), Verona (Italy)

**NCT04132960**
**PHASE 2**

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

**TARGETS**  
 ERBB2

**LOCATIONS:** Lyon (France), Nice (France), Reims (France), Villejuif (France)

PRF#

**APPENDIX**

## Variants of Unknown Significance

**NOTE** One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

**CD22**  
M600T

**FLT1**  
V278I

**IGF1R**  
P190S

**IKZF1**  
R423C

**PDCD1LG2 (PD-L2)**  
E11fs\*7

**RARA**  
amplification

**SPOP**  
amplification

**SUFU**  
S410F

*The content provided as a professional service by Foundation Medicine, Inc., has not been reviewed or approved by the FDA.*

Electronically signed by J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director | 31 January 2020 | Foundation Medicine, Inc. | Roche Customer Care: +49 7624 14 2098 or [europe.foundationmedicine@roche.com](mailto:europe.foundationmedicine@roche.com)

Sample Preparation: FMI Germany GmbH, Nonnenwald 2, 82377 Penzberg, Germany  
 Sample Analysis: FMI Germany GmbH, Nonnenwald 2, 82377 Penzberg, Germany

PRF#

APPENDIX

Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

**DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS**

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTK	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2C
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKARIA	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOCS1
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

**DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS**

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSPO2	SDC4	SLC34A2	TERC*	TERT**	TMPRSS2

\*TERC is an NCRNA

\*\*Promoter region of TERT is interrogated

**ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER GENOMIC SIGNATURES**

- Loss of Heterozygosity (LOH) score
- Microsatellite (MS) status
- Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Ciplastraat 3, 2440 Geel, Belgium.



### ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:  
[www.rochefoundationmedicine.com/f1cdxtech](http://www.rochefoundationmedicine.com/f1cdxtech).

### INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

### TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes. Using an Illumina® HiSeq platform, hybrid

capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

### THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: The association of a therapy with a genomic alteration or signature does not necessarily indicate pharmacologic effectiveness (or lack thereof); no association of a therapy with a genomic alteration or signature does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness).

### Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

### Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

### Ranking of Alterations and Therapies

*Genomic Signatures and Gene Alterations*  
 Therapies are ranked based on the following

criteria: Therapies approved in the EU in patient's tumor type (ranked alphabetically within each NCCN category) followed by therapies approved in the EU in another tumor type (ranked alphabetically within each NCCN category).

### Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

### NCCN Categorization

Genomic signatures and gene alterations detected may be associated with certain National Comprehensive Cancer Network (NCCN) Compendium drugs or biologics ([www.nccn.org](http://www.nccn.org)). The NCCN categories indicated reflect the highest possible category for a given therapy in association with each genomic signature or gene alteration. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories please refer to the NCCN Compendium.

### Limitations

1. The MSI-H/MSS designation by FMI F1CDx test is based on genome wide analysis of 95 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines. The threshold for MSI-H/MSS was determined by analytical concordance to comparator assays (IHC and PCR) using uterine, cecum and colorectal cancer FFPE tissue. The clinical validity of the qualitative MSI designation has not been established. For Microsatellite Instability (MSI) results, confirmatory testing using a validated orthogonal method should be considered.
2. TMB by F1CDx is defined based on counting the total number of all synonymous and nonsynonymous variants present at 5% allele frequency or greater (after filtering) and reported as mutations per megabase (mut/Mb) unit rounded to the nearest integer. The clinical validity of TMB defined by this panel has not been established.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH.

PRF#

APPENDIX

About FoundationOne®CDx

Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

PRF#

**LEVEL OF EVIDENCE NOT PROVIDED**

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

**NO GUARANTEE OF CLINICAL BENEFIT**

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

**NO GUARANTEE OF REIMBURSEMENT**

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

**TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN**

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

**SELECT ABBREVIATIONS**

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

PDF Service version: 2.6.0

**The median exon coverage for this sample is 550x**

PRF#

1. Gatalica Z, Snyder C, Maney T, et al. ePub Dec 2014 (2014) PMID: 25392179
2. Kroemer G, Galluzzi L, Zitvogel L, et al. 4 (7):e1058597 (2015) PMID: 26140250
3. Lal N, Beggs AD, Willcox BE, et al. 4 (3):e976052 (2015) PMID: 25949894
4. Le DT, Uram JN, Wang H, et al. ePub Jun 2015 (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Adem C, Soderberg CL, Cunningham JM, et al. 107 (4):580-2 (2003) PMID: 14520695
7. Anbazhagan R, Fujii H, Gabrielson E 5 (4):839-44 (1999) PMID: 10213220
8. Walsh MD, Buchanan DD, Cummings MC, et al. 16 (7):2214-24 (2010) PMID: 20215533
9. Risinger JI, Barrett JC, Watson P, et al. 77 (9):1836-43 (1996) PMID: 8646682
10. de Leeuw WJ, van Puijenbroek M, Tollenaar RA, et al. 63 (5):1148-9 (2003) PMID: 12615735
11. Shanley S, Fung C, Milliken J, et al. ePub 2009 (2009) PMID: 19123071
12. Buerki N, Gautier L, Kovac M, et al. ePub Jan 2012 (2012) PMID: 22034109
13. Yee CJ, Roodi N, Verrier CS, et al. 54 (7):1641-4 (1994) PMID: 8137273
14. Kamat N, Khidhir MA, Jaloudi M, et al. ePub Aug 2012 (2012) PMID: 22928966
15. Kocarnik JM, Shiovitz S, Phipps AI 3 (4):269-76 (2015) PMID: 26337942
16. You JF, Buhard O, Ligtenberg MJ, et al. ePub Dec 2010 (2010) PMID: 21081928
17. Bairwa NK, Saha A, Gochhait S, et al. ePub 2014 (2014) PMID: 24623249
18. Boland CR, Thibodeau SN, Hamilton SR, et al. 58 (22):5248-57 (1998) PMID: 9823339
19. Pawlik TM, Raut CP, Rodriguez-Bigas MA 20 (4-5):199-206 (2004) PMID: 15528785
20. Boland CR, Goel A ePub Jun 2010 (2010) PMID: 20420947
21. Samstein RM, Lee CH, Shoushtari AN, et al. ePub 02 2019 (2019) PMID: 30643254
22. Goodman AM, Kato S, Bazhenova L, et al. ePub 11 2017 (2017) PMID: 28835386
23. Goodman AM, Sokol ES, Frampton GM, et al. ePub Oct 2019 (2019) PMID: 31405947
24. Cristescu R, Mogg R, Ayers M, et al. ePub 10 2018 (2018) PMID: 30309915
25. Legrand et al., 2018; ASCO Abstract 12000
26. Chalmers ZR, Connelly CF, Fabrizio D, et al. ePub 04 2017 (2017) PMID: 28420421
27. null ePub Oct 2012 (2012) PMID: 23000897
28. Sokol ES, Feng YX, Jin DX, et al. ePub 01 2019 (2019) PMID: 30423024
29. Haricharan S, Bainbridge MN, Scheet P, et al. ePub Jul 2014 (2014) PMID: 24839032
30. Budczies J, Bockmayr M, Denkert C, et al. 1 (4):225-38 (2015) PMID: 27499907
31. Pfeifer GP, You YH, Besaratinia A 571 (1-2):19-31 (2005) PMID: 15748635
32. Hill VK, Gartner JJ, Samuels Y, et al. ePub 2013 (2013) PMID: 23875803
33. Pfeifer GP, Denissenko MF, Olivier M, et al. 21 (48):7435-51 (2002) PMID: 12379884
34. Rizvi NA, Hellmann MD, Snyder A, et al. ePub Apr 2015 (2015) PMID: 25765070
35. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. ePub May 2013 (2013) PMID: 23636398
36. Briggs S, Tomlinson I ePub Jun 2013 (2013) PMID: 23447401
37. Heitzer E, Tomlinson I ePub Feb 2014 (2014) PMID: 24583393
38. null ePub Jul 2012 (2012) PMID: 22810696
39. Roberts SA, Gordenin DA ePub 12 2014 (2014) PMID: 25568919
40. Shimizu T, Tolcher AW, Papadopoulos KP, et al. 18 (8):2316-25 (2012) PMID: 22261800
41. Seol YM, Kwon CH, Lee SJ, et al. 12 (2):301-307 (2019) PMID: 30448735
42. Shah SP, Roth A, Goya R, et al. ePub Apr 2012 (2012) PMID: 22495314
43. Ciriello G, Gatza ML, Beck AH, et al. ePub Oct 2015 (2015) PMID: 26451490
44. Kirkegaard T, Witton CJ, Edwards J, et al. ePub Jan 2010 (2010) PMID: 20102399
45. O'Hurley G, Daly E, O'Grady A, et al. ePub Apr 2014 (2014) PMID: 24138071
46. Nakatani K, Thompson DA, Barthel A, et al. 274 (31):21528-32 (1999) PMID: 10419456
47. Cicenas J, Urban P, Vuaroqueaux V, et al. ePub 2005 (2005) PMID: 15987444
48. Gonzalez E, McGraw TE ePub Aug 2009 (2009) PMID: 19597332
49. Gao J, Aksoy BA, Dogrusoz U, et al. ePub Apr 2013 (2013) PMID: 23550210
50. Zack TI, Schumacher SE, Carter SL, et al. ePub Oct 2013 (2013) PMID: 24071852
51. Beroukhim R, Mermel CH, Porter D, et al. ePub Feb 2010 (2010) PMID: 20164920
52. Slamon DJ, Leyland-Jones B, Shak S, et al. 344 (11):783-92 (2001) PMID: 11248153
53. Bang YJ, Van Cutsem E, Feyereislova A, et al. ePub Aug 2010 (2010) PMID: 20728210
54. Chumsri S, Weidler J, Ali S, et al. ePub Sep 2015 (2015) PMID: 26358791
55. Cappuzzo F, Bemis L, Varella-Garcia M ePub Jun 2006 (2006) PMID: 16775247
56. Falchook GS, Janku F, Tsao AS, et al. ePub Feb 2013 (2013) PMID: 23328556
57. Mazières J, Peters S, Lepage B, et al. ePub Jun 2013 (2013) PMID: 23610105
58. Baselga J, Cortés J, Kim SB, et al. ePub Jan 2012 (2012) PMID: 22149875
59. Swain SM, Baselga J, Kim SB, et al. ePub Feb 2015 (2015) PMID: 25693012
60. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. ePub Apr 2019 (2019) PMID: 30857956
61. Bang YJ, Giaccone G, Im SA, et al. ePub 04 2017 (2017) PMID: 28119295
62. Meric-Bernstam et al., 2019; ESMO Abstract 453PD
63. Verma S, Miles D, Gianni L, et al. ePub Nov 2012 (2012) PMID: 23020162
64. Modi S, Saura C, Yamashita T, et al. ePub Dec 2019 (2019) PMID: 31825192
65. Borges VF, Ferrario C, Aucoin N, et al. ePub Sep 2018 (2018) PMID: 29955792
66. Murthy R, Borges VF, Conlin A, et al. ePub 07 2018 (2018) PMID: 29804905
67. Moulder SL, Borges VF, Baetz T, et al. 23 (14):3529-3536 (2017) PMID: 28053022
68. Cameron D, Casey M, Oliva C, et al. ePub 2010 (2010) PMID: 20736298
69. Geyer CE, Forster J, Lindquist D, et al. ePub Dec 2006 (2006) PMID: 17192538
70. Serra V, Vivancos A, Puente XS, et al. ePub Nov 2013 (2013) PMID: 23950206
71. Ali SM, Alpaugh RK, Downing SR, et al. ePub Sep 2014 (2014) PMID: 24516025
72. Grellety T, Soubeyran I, Robert J, et al. ePub Jan 2016 (2016) PMID: 26487584
73. Bedard et al., 2019; AACR Abstract CT139/5
74. Lin NU, Winer EP, Wheatley D, et al. ePub Jun 2012 (2012) PMID: 22418700
75. Schwab CL, Bellone S, English DP, et al. ePub Oct 2014 (2014) PMID: 25268372
76. De Grève J, Teugels E, Geers C, et al. ePub Apr 2012 (2012) PMID: 22325357
77. De Grève J, Moran T, Graas MP, et al. ePub Apr 2015 (2015) PMID: 25682316
78. Li BT, Lee A, O'Toole S, et al. ePub Dec 2015 (2015) PMID: 26559459
79. Gandhi L, Bahlreda R, Tolaney SM, et al. ePub Jan 2014 (2014) PMID: 24323026
80. Ben-Baruch NE, Bose R, Kavuri SM, et al. ePub Sep 2015 (2015) PMID: 26358790
81. Kris MG, Camidge DR, Giaccone G, et al. ePub Jul 2015 (2015) PMID: 25899785
82. Jiang et al., 2019; ASCO Abstract 1001
83. Rugo et al., 2019; ASCO Abstract 1000
84. Li Q, Guan X, Chen S, et al. 25 (17):5212-5220 (2019) PMID: 31138588
85. Ma F, Ouyang Q, Li W, et al. ePub Aug 2019 (2019) PMID: 31430226
86. Jones KL, Buzdar AU ePub Dec 2009 (2009) PMID: 19959074
87. Zagouri F, Sergentanis TN, Chrysikos D, et al. ePub Oct 2013 (2013) PMID: 23870456
88. Banerji S, Cibulskis K, Rangel-Escareno C, et al. ePub Jun 2012 (2012) PMID: 22722202
89. Ross JS, Gay LM, Wang K, et al. ePub 09 2016 (2016) PMID: 27284958
90. Ross JS, Wang K, Sheehan CE, et al. 19 (10):2668-76 (2013) PMID: 23575477
91. Chmielecki J, Ross JS, Wang K, et al. ePub Jan 2015 (2015) PMID: 25480824
92. null ePub Mar 2012 (2012) PMID: 22461643
93. Ramić S, Asić K, Balja MP, et al. ePub Jun 2013 (2013) PMID: 23749902
94. Higgins MJ, Baselga J ePub Oct 2011 (2011) PMID: 21965336
95. Wander SA, Hennessy BT, Slingerland JM ePub Apr 2011 (2011) PMID: 21490404
96. Schenone S, Brullo C, Musumeci F, et al. ePub 2011 (2011) PMID: 21651476
97. André F, Bachelot T, Commo F, et al. ePub Mar 2014 (2014) PMID: 24508104
98. Johnson DB, Dahlman KH, Knol J, et al. ePub Jun 2014 (2014) PMID: 24797823
99. Pereira B, Chin SF, Rueda OM, et al. ePub May 2016 (2016) PMID: 27161491
100. Stephens PJ, Tarpey PS, Davies H, et al. ePub May 2012 (2012) PMID: 22722201
101. Wazir U, Newbold RF, Jiang WG, et al. ePub May 2013 (2013) PMID: 23503572
102. García-García C, Ibrahim YH, Serra V, et al. 18 (9):2603-12 (2012) PMID: 22407832
103. Wen ZH, Su YC, Lai PL, et al. ePub Jan 2013 (2013) PMID: 22349822

PRF#

104. Kim DH, Sarbassov DD, Ali SM, et al. 110 (2):163-75 (2002) PMID: 12150925
105. Hara K, Maruki Y, Long X, et al. 110 (2):177-89 (2002) PMID: 12150926
106. Hirai H, Arai T, Okada M, et al. ePub Apr 2010 (2010) PMID: 20107315
107. Bridges KA, Hirai H, Buser CA, et al. 17 (17):5638-48 (2011) PMID: 21799033
108. Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. 17 (9):2799-806 (2011) PMID: 21389100
109. Osman AA, Monroe MM, Ortega Alves MV, et al. ePub Feb 2015 (2015) PMID: 25504633
110. Xu L, Huang CC, Huang W, et al. 1 (5):337-46 (2002) PMID: 12489850
111. Xu L, Tang WH, Huang CC, et al. 7 (10):723-34 (2001) PMID: 11713371
112. Camp ER, Wang C, Little EC, et al. ePub Apr 2013 (2013) PMID: 23470564
113. Kim SS, Rait A, Kim E, et al. ePub Feb 2015 (2015) PMID: 25240597
114. Pirollo KF, Nemunaitis J, Leung PK, et al. ePub Sep 2016 (2016) PMID: 27357628
115. Hajdenberg et al., 2012; ASCO Abstract e15010
116. Lehmann S, Bykov VJ, Ali D, et al. ePub Oct 2012 (2012) PMID: 22965953
117. Mohell N, Alfreðsson J, Fransson Å, et al. ePub Jun 2015 (2015) PMID: 26086967
118. Fransson Å, Glaessgen D, Alfreðsson J, et al. ePub May 2016 (2016) PMID: 27179933
119. Gourley et al., 2016; ASCO Abstract 5571
120. Leijen S, van Geel RM, Pavlick AC, et al. ePub Dec 2016 (2016) PMID: 27601554
121. Moore et al., 2019; ASCO Abstract 5513
122. Leijen S, van Geel RM, Sonke GS, et al. ePub 12 2016 (2016) PMID: 27998224
123. Oza et al., 2015; ASCO Abstract 5506
124. Méndez E, Rodríguez CP, Kao MC, et al. 24 (12):2740-2748 (2018) PMID: 29535125
125. Ma CX, Cai S, Li S, et al. ePub Apr 2012 (2012) PMID: 22446188
126. Alsner J, Jensen V, Kyndi M, et al. ePub 2008 (2008) PMID: 18465328
127. Alkam Y, Mitomi H, Nakai K, et al. ePub Nov 2013 (2013) PMID: 24004112
128. Uji K, Naoi Y, Kagara N, et al. ePub Jan 2014 (2014) PMID: 23973262
129. Olivier M, Langerød A, Carrieri P, et al. 12 (4):1157-67 (2006) PMID: 16489069
130. Végran F, Rebucci M, Chevrier S, et al. ePub 2013 (2013) PMID: 23359294
131. Walsh T, Casadei S, Coats KH, et al. ePub Mar 2006 (2006) PMID: 16551709
132. Garber JE, Offit K 23 (2):276-92 (2005) PMID: 15637391
133. Apostolou P, Fostira F ePub 2013 (2013) PMID: 23586058
134. Brown CJ, Lain S, Verma CS, et al. ePub Dec 2009 (2009) PMID: 19935675
135. Joerger AC, Fersht AR 77 :557-82 (2008) PMID: 18410249
136. Kato S, Han SY, Liu W, et al. 100 (14):8424-9 (2003) PMID: 12826609
137. Kamada R, Nomura T, Anderson CW, et al. ePub Jan 2011 (2011) PMID: 20978130
138. Landrum MJ, Lee JM, Benson M, et al. ePub 01 2018 (2018) PMID: 29165669
139. Bougeard G, Renaux-Petel M, Flaman JM, et al. ePub Jul 2015 (2015) PMID: 26014290
140. Sorrell AD, Espenschied CR, Culver JO, et al. ePub Feb 2013 (2013) PMID: 23355100
141. Nichols KE, Malkin D, Garber JE, et al. 10 (2):83-7 (2001) PMID: 11219776
142. Kleihues P, Schäuble B, zur Hausen A, et al. 150 (1):1-13 (1997) PMID: 9006316
143. Gonzalez KD, Noltner KA, Buzin CH, et al. ePub Mar 2009 (2009) PMID: 19204208
144. Laloo F, Varley J, Ellis D, et al. 361 (9363):1101-2 (2003) PMID: 12672316
145. Mandelker D, Donoghue M, Talukdar S, et al. ePub 08 2009 (2019) PMID: 31050713
146. Wheler et al., 2014; San Antonio Breast Cancer Symposium Abstract P2-05-03
147. Beck JT, Hortobagyi GN, Campone M, et al. ePub Feb 2009 (2009) PMID: 24362951
148. Yardley DA, Noguchi S, Pritchard KI, et al. ePub Oct 2013 (2013) PMID: 24158787
149. Baselga J, Campone M, Piccart M, et al. ePub Feb 2012 (2012) PMID: 22149876
150. Piccart M, Hortobagyi GN, Campone M, et al. ePub Dec 2014 (2014) PMID: 25231953
151. Jerusalem G, de Boer RH, Hurvitz S, et al. ePub Jun 2018 (2018) PMID: 29862411
152. Moynahan ME, Chen D, He W, et al. ePub Mar 2017 (2017) PMID: 28183140
153. Baselga J, Semiglazov V, van Dam P, et al. ePub Jun 2009 (2009) PMID: 19380449
154. Bachelot T, Bourcier C, Cropet C, et al. ePub Aug 2012 (2012) PMID: 22565002
155. Wheler JJ, Moulder SL, Naing A, et al. ePub May 2014 (2014) PMID: 24912489
156. Hurvitz SA, Andre F, Jiang Z, et al. ePub Jul 2015 (2015) PMID: 26092818
157. André F, O'Regan R, Ozguroglu M, et al. ePub May 2014 (2014) PMID: 24742739
158. Slamon et al., 2015; ASCO Abstract 512
159. André F, Hurvitz S, Fasola A, et al. ePub Jun 2016 (2016) PMID: 27091708
160. Singh J, Novik Y, Stein S, et al. ePub Mar 2014 (2014) PMID: 24684785
161. Tolcher AW, Bendell JC, Papadopoulos KP, et al. ePub Jan 2015 (2015) PMID: 25344362
162. Patterson et al., 2018; AACR Abstract 3891
163. Bian L, Wang T, Zhang S, et al. ePub Oct 2013 (2013) PMID: 23729232
164. Baselga J, Bradbury J, Eidtmann H, et al. ePub Feb 2012 (2012) PMID: 22257673
165. Robidoux A, Tang G, Rastogi P, et al. ePub Nov 2013 (2013) PMID: 24095300
166. Alba E, Albanell J, de la Haba J, et al. ePub Mar 2014 (2014) PMID: 24457911
167. Gelmon KA, Boyle FM, Kaufman B, et al. ePub May 2015 (2015) PMID: 25779558
168. Bachelot T, Romieu G, Campone M, et al. ePub Jan 2013 (2013) PMID: 23122784
169. Pivot X, Manikhas A, Żurawski B, et al. ePub May 2015 (2015) PMID: 25605838
170. Krop IE, Lin NU, Blackwell K, et al. ePub Jan 2015 (2015) PMID: 25355722
171. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. ePub Sep 2014 (2014) PMID: 25130998
172. Piccart-Gebhart M, Holmes E, Baselga J, et al. ePub Apr 2016 (2016) PMID: 26598744
173. Goss PE, Smith IE, O'Shaughnessy J, et al. ePub Jan 2013 (2013) PMID: 23234763
174. Johnston S, Pippen J, Pivot X, et al. ePub Nov 2009 (2009) PMID: 19786658
175. Burstein HJ, Cirrincione CT, Barry WT, et al. ePub Dec 2014 (2014) PMID: 25348000
176. Guarneri V, Generali DG, Frassoldati A, et al. ePub Apr 2014 (2014) PMID: 24590635
177. Coombes RC, Tat T, Miller ML, et al. ePub Apr 2013 (2013) PMID: 23233650
178. Hyman et al., 2016; San Antonio Breast Cancer Symposium Abstract PD2-08
179. Ma CX, Bose R, Gao F, et al. 23 (19):5687-5695 (2017) PMID: 28679771
180. Chan A, Delalage S, Holmes FA, et al. ePub Mar 2016 (2016) PMID: 26874901
181. Park JW, Liu MC, Yee D, et al. ePub Jul 2016 (2016) PMID: 27406346
182. Schwab CL, English DP, Black J, et al. ePub Oct 2015 (2015) PMID: 26260909
183. Menderes G, Bonazzoli E, Bellone S, et al. ePub May 2017 (2017) PMID: 28397106
184. Hu Z, Hu Y, Liu X, et al. ePub Oct 2015 (2015) PMID: 26375550
185. Kavuri SM, Jain N, Galimi F, et al. ePub Aug 2015 (2015) PMID: 26243863
186. Bose R, Kavuri SM, Searleman AC, et al. ePub Feb 2013 (2013) PMID: 23220880
187. Martin M, Holmes FA, Ejlertsen B, et al. ePub Dec 2017 (2017) PMID: 29146401
188. Chia et al., 2017; SABCS Abstract P1-13-03
189. Ejlertsen et al., 2017; SABCS Abstract P1-13-05
190. Burstein HJ, Sun Y, Dirix LY, et al. ePub Mar 2010 (2010) PMID: 20142587
191. Martin M, Bonnetterre J, Geyer CE, et al. ePub Dec 2013 (2013) PMID: 23953056
192. Freedman RA, Gelman RS, Wefel JS, et al. ePub Mar 2016 (2016) PMID: 26834058
193. Saura et al., 2019; ASCO Abstract 1002
194. Chow LW, Xu B, Gupta S, et al. ePub May 2013 (2013) PMID: 23632474
195. Jankowitz RC, Abraham J, Tan AR, et al. ePub Dec 2013 (2013) PMID: 24077916
196. Awada A, Dirix L, Manso Sanchez L, et al. ePub Jan 2013 (2013) PMID: 22967996
197. Awada A, Colomer R, Inoue K, et al. ePub Dec 2016 (2016) PMID: 27078022
198. Hurvitz SA, Martin M, Symmans WF, et al. ePub Jan 2018 (2018) PMID: 29175149
199. von Minckwitz G, Procter M, de Azambuja E, et al. ePub 07 2017 (2017) PMID: 28581356
200. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. ePub Feb 2018 (2018) PMID: 29320312
201. Swain SM, Kim SB, Cortés J, et al. ePub May 2013 (2013) PMID: 23602601
202. Gianni L, Pienkowski T, Im YH, et al. ePub Jan 2012 (2012) PMID: 22153890
203. Gianni L, Pienkowski T, Im YH, et al. ePub Jun 2016 (2016) PMID: 27179402
204. Krop IE, Modi S, LoRusso PM, et al. ePub Mar 2016 (2016) PMID: 26979312
205. Urruticoechea et al., 2016; ASCO Abstract 504
206. Iyengar et al., 2016; ASCO Abstract 611
207. Soliman et al., 2016; ASCO Abstract 595



PRF#

208. Gianni L, Eiermann W, Semiglazov V, et al. ePub May 2014 (2014) PMID: 24657003
209. Morris PG, Iyengar NM, Patil S, et al. ePub Nov 2013 (2013) PMID: 24037735
210. Wang K, Russell JS, McDermott JD, et al. 22 (24):6061-6068 (2016) PMID: 27334835
211. Nishikawa K, Takahashi T, Takaishi H, et al. ePub Jan 2017 (2017) PMID: 27521503
212. Singer CF, Tan YY, Fitzal F, et al. 23 (14):3676-3683 (2017) PMID: 28143867
213. von Minckwitz G, Colleoni M, Kolberg HC, et al. ePub 07 2018 (2018) PMID: 29880292
214. Hanes V, Chow V, Zhang N, et al. ePub May 2017 (2017) PMID: 28341959
215. Rugo et al., 2016; ASCO Abstract LBA503
216. Waller et al., 2016; ASCO Abstract 583
217. Audran et al., 2017; ASCO-SITC Clinical Immunology-Oncology Symposium Abstract 10
218. Pivov X, Bondarenko I, Nowecki Z, et al. ePub Apr 2018 (2018) PMID: 29373094
219. Pivov X, Bondarenko I, Nowecki Z, et al. ePub 04 2018 (2018) PMID: 29448072
220. Stebbing et al., 2017; 28592386; Esteva et al.
221. Lammers PE, Dank M, Masetti R, et al. ePub Aug 2018 (2018) PMID: 30002437
222. Pegram MD, Bondarenko I, Zorzetto MMC, et al. ePub Jan 2019 (2019) PMID: 30568294
223. Earl HM, Hiller L, Vallier AL, et al. ePub 06 2019 (2019) PMID: 31178152
224. Pivov X, Romieu G, Debled M, et al. ePub 06 2019 (2019) PMID: 31178155
225. Krop IE, Kim SB, González-Martín A, et al. ePub Jun 2014 (2014) PMID: 24793816
226. Welslau M, Diéras V, Sohn JH, et al. ePub Mar 2014 (2014) PMID: 24222194
227. Baselga J, Lewis Phillips GD, Verma S, et al. 22 (15):3755-63 (2016) PMID: 26920887
228. Perez EA, Barrios C, Eiermann W, et al. ePub Jan 2017 (2017) PMID: 28056202
229. Hurvitz SA, Dirix L, Kocsis J, et al. ePub Mar 2013 (2013) PMID: 23382472
230. von Minckwitz G, Huang CS, Mano MS, et al. ePub 02 2019 (2019) PMID: 30516102
231. Hurvitz SA, Martin M, Jung KH, et al. ePub Sep 2019 (2019) PMID: 31157583
232. Martin M, Fumoleau P, Dewar JA, et al. ePub 07 2016 (2016) PMID: 27052654
233. Abraham J, Montero AJ, Jankowitz RC, et al. ePub Aug 2019 (2019) PMID: 31442103
234. Jain et al., 2016; ASCO Abstract 588
235. McCabe et al., 2016; ASCO Abstract 582
236. Dziadziuszko R, Smit EF, Dafni U, et al. ePub Jun 2019 (2019) PMID: 30825613
237. Lai WV, Lebas L, Barnes TA, et al. ePub Mar 2019 (2019) PMID: 30685684
238. Liu Z, Wu L, Cao J, et al. 11:7323-7331 (2018) PMID: 30425522
239. Fang W, Zhao S, Liang Y, et al. ePub Nov 2019 (2019) PMID: 31748336
240. Greulich H, Kaplan B, Mertins P, et al. ePub Sep 2012 (2012) PMID: 22908275
241. Robichaux JP, Elamin YY, Vijayan RSK, et al. ePub Oct 2019 (2019) PMID: 31588020
242. Jang J, Son J, Park E, et al. ePub 09 2018 (2018) PMID: 29978938
243. Koga T, Kobayashi Y, Tomizawa K, et al. ePub 12 2018 (2018) PMID: 30527195
244. Harbeck N, Huang CS, Hurvitz S, et al. ePub Mar 2016 (2016) PMID: 26822398
245. Cortés J, Dieras V, Ro J, et al. ePub Dec 2015 (2015) PMID: 26596672
246. Rimawi MF, Aleixo SB, Rozas AA, et al. ePub Apr 2015 (2015) PMID: 25537159
247. Schuler M, Awada A, Harter P, et al. ePub Aug 2012 (2012) PMID: 22763464
248. Gunzer K, Joly F, Ferrero JM, et al. 5:45 (2016) PMID: 26835225
249. Jänne PA, Boss DS, Camidge DR, et al. 17 (5):1131-9 (2011) PMID: 21220471
250. Reckamp KL, Giaccone G, Camidge DR, et al. ePub Apr 2014 (2014) PMID: 24501009
251. Kim HS, Kwon HJ, Jung I, et al. 21 (3):544-52 (2015) PMID: 25424851
252. Oh DY, Lee KW, Cho JY, et al. ePub Oct 2016 (2016) PMID: 26581547
253. Kalous O, Conklin D, Desai AJ, et al. ePub Sep 2012 (2012) PMID: 22761403
254. Zhu L, Lopez S, Bellone S, et al. ePub Jul 2015 (2015) PMID: 25669172
255. Tilio M, Gambini V, Wang J, et al. ePub 10 2016 (2016) PMID: 27475932
256. Kosaka T, Tanizaki J, Paranal RM, et al. ePub 05 2017 (2017) PMID: 28363995
257. Opsomer RJ, Wese FX, Van Gangh PJ 53 (1):89-95 (1985) PMID: 2986437
258. Wu YL, Cheng Y, Zhou X, et al. ePub Nov 2017 (2017) PMID: 28598502
259. Necchi et al., 2018; ASCO Abstract 399
260. Necchi A, Lo Vullo S, Perrone F, et al. ePub 03 2018 (2018) PMID: 28921872
261. Kim HS, Kim SM, Kim H, et al. ePub Dec 2015 (2015) PMID: 26462025
262. Cavaliere S, Perrone F, Miceli R, et al. ePub Jul 2018 (2018) PMID: 29734047
263. Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, et al. ePub Oct 2017 (2017) PMID: 28575464
264. Moroney JW, Schlumbrecht MP, Helgason T, et al. 17 (21):6840-6 (2011) PMID: 21890452
265. Moroney J, Fu S, Moulder S, et al. 18 (20):5796-805 (2012) PMID: 22927482
266. Fleming GF, Ma CX, Huo D, et al. ePub Nov 2012 (2012) PMID: 22245973
267. Wolff AC, Lazar AA, Bondarenko I, et al. ePub Jan 2013 (2013) PMID: 23233719
268. Moulder S, Helgason T, Janku F, et al. ePub Jul 2015 (2015) PMID: 25878190

